

Larry W Moreland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9327888/publications.pdf>

Version: 2024-02-01

241
papers

39,463
citations

9264

74
h-index

2629

194
g-index

253
all docs

253
docs citations

253
times ranked

30132
citing authors

#	ARTICLE	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
2	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.9	2,994
3	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	27.8	1,974
4	A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1586-1593.	27.0	1,776
5	Adalimumab, a fully human anti-tumor necrosis factor β monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 35-45.	6.7	1,612
6	Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75) α Fc Fusion Protein. <i>New England Journal of Medicine</i> , 1997, 337, 141-147.	27.0	1,586
7	2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 625-639.	3.4	1,413
8	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 762-784.	6.7	1,311
9	Etanercept Therapy in Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 1999, 130, 478.	3.9	1,176
10	Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. <i>New England Journal of Medicine</i> , 2006, 354, 795-808.	27.0	1,127
11	Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4lg. <i>New England Journal of Medicine</i> , 2003, 349, 1907-1915.	27.0	973
12	Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. <i>Nature Immunology</i> , 2019, 20, 928-942.	14.5	760
13	Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. <i>Arthritis and Rheumatism</i> , 2002, 46, 1443-1450.	6.7	664
14	Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2006, 144, 865.	3.9	643
15	Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 614-624.	6.7	570
16	Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 1412-1419.	6.7	478
17	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIB, double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 2263-2271.	6.7	456
18	Golimumab, a human anti-tumor necrosis factor β monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2272-2283.	6.7	387

#	ARTICLE	IF	CITATIONS
19	Costimulatory blockade in patients with rheumatoid arthritis: A pilot, doseâ€nding, doubleâ€blind, placeboâ€controlled clinical trial evaluating CTLAâ€4Ig and LEA29Y eightyâ€five days after the first infusion. <i>Arthritis and Rheumatism</i> , 2002, 46, 1470-1479.	6.7	354
20	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial. <i>Arthritis and Rheumatism</i> , 2012, 64, 2824-2835.	6.7	325
21	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1999, 42, 1194-1203.	6.7	312
22	REL, encoding a member of the NF-ÎB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. <i>Nature Genetics</i> , 2009, 41, 820-823.	21.4	305
23	Demyelinating and neurologic events reported in association with tumor necrosis factor ? antagonism: By what mechanisms could tumor necrosis factor ? antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. <i>Arthritis and Rheumatism</i> , 2001, 44, 1977-1983.	6.7	296
24	Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. <i>Clinical Therapeutics</i> , 2003, 25, 1700-1721.	2.5	279
25	Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. <i>Arthritis and Rheumatism</i> , 2001, 44, 1984-1992.	6.7	275
26	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 837-845.	5.6	271
27	Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. <i>Arthritis and Rheumatism</i> , 2000, 43, 2445-2454.	6.7	252
28	Effects of doxycycline on progression of osteoarthritis: Results of a randomized, placeboâ€controlled, doubleâ€blind trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 2015-2025.	6.7	249
29	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
30	Recombinant Human Relaxin in the Treatment of Scleroderma. <i>Annals of Internal Medicine</i> , 2000, 132, 871.	3.9	220
31	Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1460-1469.	6.7	219
32	Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 2983-2989.	6.7	194
33	Phenome-Wide Association Study (PheWAS) for Detection of Pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network. <i>PLoS Genetics</i> , 2013, 9, e1003087.	3.5	171
34	The influence of genetic variation in the HLA-DRB1 andLTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. <i>Arthritis and Rheumatism</i> , 2004, 50, 2750-2756.	6.7	163
35	Results of a twoâ€year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. <i>Arthritis and Rheumatism</i> , 2008, 58, 953-963.	6.7	159
36	Abatacept. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 185-186.	46.4	158

#	ARTICLE	IF	CITATIONS
37	Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycolâ€‘conjugated uricase) in patients with treatmentâ€‘failure gout: Results of a phase II randomized study. <i>Arthritis and Rheumatism</i> , 2008, 58, 2882-2891.	6.7	156
38	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	3.5	146
39	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
40	Biologic agents for treating rheumatoid arthritis. Concepts and progress. <i>Arthritis and Rheumatism</i> , 1997, 40, 397-409.	6.7	143
41	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, doubleâ€‘blind, placeboâ€‘controlled trial. <i>Arthritis and Rheumatism</i> , 2009, 60, 1102-1111.	6.7	137
42	Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 307-318.	6.7	134
43	Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 2858-2868.	6.7	133
44	Efficacy and Safety of Intraarticular Sodium Hyaluronate in Knee Osteoarthritis. <i>Clinical Orthopaedics and Related Research</i> , 2001, 385, 130-143.	1.5	132
45	A Randomized, Doubleâ€‘Blind Trial of Abatacept (CTLAâ€‘4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	5.6	131
46	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibodyâ€‘Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1054-1066.	5.6	130
47	Changes in Lipoproteins Associated With Methotrexate Therapy or Combination Therapy in Early Rheumatoid Arthritis: Results From the Treatment of Early Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 1430-1438.	6.7	124
48	Inflammatory central nervous system involvement in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1989, 18, 258-266.	3.4	122
49	Treatment of refractory rheumatoid arthritis with a chimeric ANTI-CD4 monoclonal antibody. <i>Arthritis and Rheumatism</i> , 1994, 37, 834-838.	6.7	118
50	Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study. <i>Journal of Rheumatology</i> , 2009, 36, 736-742.	2.0	114
51	Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program. <i>Journal of Rheumatology</i> , 2013, 40, 787-797.	2.0	112
52	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	3.4	109
53	Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-cd4 antibody, cm-t412, in rheumatoid arthritis patients receiving concomitant methotrexate. <i>Arthritis and Rheumatism</i> , 1995, 38, 1581-1588.	6.7	107
54	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. <i>Journal of Rheumatology</i> , 2005, 32, 832-40.	2.0	107

#	ARTICLE	IF	CITATIONS
55	Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six-month, double-blind, randomized, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2002, 46, 2020-2028.	6.7	106
56	Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 257-265.	6.7	101
57	A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. <i>Arthritis and Rheumatism</i> , 2008, 58, 1810-1822.	6.7	99
58	Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. <i>Clinical Therapeutics</i> , 2000, 22, 128-139.	2.5	97
59	Validation of American College of Rheumatology Classification Criteria for Knee Osteoarthritis Using Arthroscopically Defined Cartilage Damage Scores. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 197-201.	3.4	97
60	Vitamin D Status and Its Associations with Disease Activity and Severity in African Americans with Recent-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 275-281.	2.0	97
61	Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2372-2380.	6.7	96
62	The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2001, 44, 653-661.	6.7	96
63	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti-tumor necrosis factor therapy. <i>Arthritis and Rheumatism</i> , 2010, 62, 1849-1861.	6.7	95
64	Sedentary Behavior and Mortality in Older Women. <i>American Journal of Preventive Medicine</i> , 2014, 46, 122-135.	3.0	94
65	Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. <i>Arthritis Research and Therapy</i> , 2018, 20, 139.	3.5	93
66	Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1232-42.	2.0	89
67	Glucocorticoids and rheumatoid arthritis: Back to the future?. <i>Arthritis and Rheumatism</i> , 2002, 46, 2553-2563.	6.7	88
68	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015, 42, 1209-1212.	2.0	87
69	Ludwig's Angina. <i>Archives of Internal Medicine</i> , 1988, 148, 461.	3.8	85
70	Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized, double-blind six-week trial with eighteen-week extension. <i>Arthritis and Rheumatism</i> , 1999, 42, 357-365.	6.7	78
71	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	6.2	78
72	Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. <i>Journal of Rheumatology</i> , 2006, 33, 854-61.	2.0	78

#	ARTICLE	IF	CITATIONS
73	Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. <i>Arthritis and Rheumatism</i> , 1996, 39, 1172-1177.	6.7	77
74	The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. <i>Arthritis and Rheumatism</i> , 2008, 58, 349-358.	6.7	77
75	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	3.4	77
76	Ultrasound detection of bone erosions in rheumatoid arthritis: a comparison to routine radiographs of the hands and feet. <i>Skeletal Radiology</i> , 2004, 33, 80-84.	2.0	75
77	Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor Inhibitors. <i>Clinical Infectious Diseases</i> , 2009, 49, 924-927.	5.8	75
78	Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. <i>American Journal of Medicine</i> , 1991, 90, 295-298.	1.5	74
79	T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides. <i>Arthritis and Rheumatism</i> , 1998, 41, 1919-1929.	6.7	73
80	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	12.8	73
81	Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 2162-6.	2.0	71
82	Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy. <i>Drug Design, Development and Therapy</i> , 2010, Volume 4, 263-278.	4.3	70
83	Cutaneous polyarteritis nodosa. <i>American Journal of Medicine</i> , 1990, 88, 426-430.	1.5	69
84	Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2311-2322.	5.6	69
85	Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. <i>Journal of Rheumatology</i> , 2003, 30, 691-6.	2.0	66
86	Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. <i>Arthritis Care and Research</i> , 2018, 70, 197-204.	3.4	65
87	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 878-891.	5.6	64
88	Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. <i>Seminars in Arthritis and Rheumatism</i> , 1989, 19, 31-44.	3.4	63
89	SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR (p75) FUSION PROTEIN (ENBREL) AS A THERAPY FOR RHEUMATOID ARTHRITIS. <i>Rheumatic Disease Clinics of North America</i> , 1998, 24, 579-591.	1.9	63
90	Interleukin-2 diphtheria fusion protein (dab486il-2) in refractory rheumatoid arthritis a double-blind, placebo-controlled trial with open-label extension. <i>Arthritis and Rheumatism</i> , 1995, 38, 1177-1186.	6.7	62

#	ARTICLE	IF	CITATIONS
91	Inter-observer reliability of the arthroscopic quantification of chondropathy of the knee. Osteoarthritis and Cartilage, 1998, 6, 160-166.	1.3	62
92	Validation of the Methotrexateâ€First Strategy in Patients With Early, Poorâ€Prognosis Rheumatoid Arthritis: Results From a Twoâ€Year Randomized, Doubleâ€Blind Trial. Arthritis and Rheumatism, 2013, 65, 1985-1994.	6.7	62
93	Drugs that block tumour necrosis factor: Experience in patients with rheumatoid arthritis. Pharmacoeconomics, 2004, 22, 39-53.	3.3	60
94	Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. American Journal of Medicine, 1991, 90, 295-298.	1.5	59
95	Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory Mechanisms. Seminars in Arthritis and Rheumatism, 2009, 39, 132-143.	3.4	59
96	Increased pretreatment serum IFN- γ ratio predicts non-response to tumour necrosis factor γ inhibition in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1757-1762.	0.9	59
97	Most common singleâ€nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. Arthritis and Rheumatism, 2010, 62, 3547-3553.	6.7	56
98	Acute febrile neutrophilic dermatosis (sweet syndrome): A review of the literature with emphasis on musculoskeletal manifestations. Seminars in Arthritis and Rheumatism, 1988, 17, 143-155.	3.4	53
99	Psoriatic arthritis: Current concepts on pathogenesis-oriented therapeutic options. Arthritis and Rheumatism, 2007, 56, 1051-1066.	6.7	53
100	Upcoming biologic agents for the treatment of rheumatic diseases. Current Opinion in Rheumatology, 2003, 15, 226-263.	4.3	50
101	Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis and Rheumatism, 2006, 55, 287-293.	6.7	50
102	High-dose versus low-dose γ -penicillamine in early diffuse systemic sclerosis trial: lessons learned. Seminars in Arthritis and Rheumatism, 2004, 33, 249-263.	3.4	49
103	Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. Journal of Rheumatology, 2004, 31, 1532-7.	2.0	49
104	Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Research and Therapy, 2016, 18, 108.	3.5	48
105	Improvement of Highâ€Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. Arthritis and Rheumatology, 2017, 69, 46-57.	5.6	48
106	Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Research, 2001, 3, 247.	2.0	45
107	TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opinion on Pharmacotherapy, 2001, 2, 75-84.	1.8	44
108	Associations of cigarette smoking with rheumatoid arthritis in African Americans. Arthritis and Rheumatism, 2010, 62, 3560-3568.	6.7	44

#	ARTICLE	IF	CITATIONS
109	Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatology</i> , 2016, 68, 577-586.	5.6	43
110	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 707-713.	3.4	43
111	Spinal stenosis: A comprehensive review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 1989, 19, 127-149.	3.4	41
112	Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1991, 60, 412-418.	2.0	40
113	Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis. <i>Drug Safety</i> , 2003, 26, 23-32.	3.2	40
114	Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. <i>Journal of the National Medical Association</i> , 2005, 97, 1155-60.	0.8	40
115	Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1245-1254.	3.1	39
116	A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs. <i>Pharmacoeconomics</i> , 2001, 19, 715-728.	3.3	37
117	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	1.9	37
118	PERIOPERATIVE USE OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS UNDERGOING ORTHOPEDIC SURGERY. <i>Rheumatic Disease Clinics of North America</i> , 1997, 23, 981-993.	1.9	36
119	Long-Term Experience with Etanercept in the Treatment of Rheumatoid Arthritis in Elderly and Younger Patients. <i>Drugs and Aging</i> , 2006, 23, 167-178.	2.7	36
120	The Safety of Flavocoxid, a Medical Food, in the Dietary Management of Knee Osteoarthritis. <i>Journal of Medicinal Food</i> , 2009, 12, 1143-1148.	1.5	36
121	Domains of health-related quality of life important to patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 819-825.	6.7	35
122	A functional <i>RANKL</i> polymorphism associated with younger age at onset of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2864-2875.	6.7	35
123	Intraarticular corticosteroid injections: Should we rest the joints?. <i>Arthritis and Rheumatism</i> , 1989, 2, 70-74.	6.7	34
124	Comparison of the Disease Activity Score Using Erythrocyte Sedimentation Rate and C-reactive Protein in African Americans with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1812-1822.	2.0	34
125	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. <i>PLoS ONE</i> , 2014, 9, e87645.	2.5	34
126	Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission. <i>Arthritis and Rheumatology</i> , 2017, 69, 1176-1186.	5.6	34

#	ARTICLE	IF	CITATIONS
127	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>ADA2</i>. <i>Arthritis and Rheumatology</i> , 2021, 73, 512-519.	5.6	34
128	Radiographic severity of Rheumatoid Arthritis in African Americans: Results from a multicenter observational study. <i>Arthritis Care and Research</i> , 2010, 62, 624-631.	3.4	33
129	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020, 59, 1118-1127.	1.9	33
130	Update on Cardiovascular Disease Risk in Patients with Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 475-487.	1.9	32
131	Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3057-3059.	6.7	31
132	Specific Cyclooxygenase 2 Inhibitors: A New Choice of Nonsteroidal Anti-Inflammatory Drug Therapy. <i>Arthritis and Rheumatism</i> , 1999, 12, 351-362.	6.7	30
133	High-resolution ultrasound for the study of target joints in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1969-1970.	6.7	30
134	Calcium and vitamin D supplementation and incident rheumatoid arthritis: the Women's Health Initiative Calcium plus Vitamin D trial. <i>Rheumatology International</i> , 2012, 32, 3823-3830.	3.0	30
135	Determinants of Mortality Among Postmenopausal Women in the Women's Health Initiative Who Report Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 497-507.	5.6	30
136	Comprehensive Appraisal of Magnetic Resonance Imaging Findings in Sustained Rheumatoid Arthritis Remission: A Substudy. <i>Arthritis Care and Research</i> , 2015, 67, 929-939.	3.4	30
137	Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2219-2226.	6.7	28
138	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 322-328.	1.9	28
139	Family Planning Counseling for Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2018, 70, 169-174.	3.4	28
140	Rheumatoid arthritis: developing pharmacological therapies. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1007-1018.	4.1	27
141	Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1751-1757.	3.4	27
142	Early rheumatoid arthritis: a medical emergency?. <i>American Journal of Medicine</i> , 2001, 111, 498-500.	1.5	26
143	Unmet needs in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2005, 7, S2.	3.5	26
144	Anti-cyclic citrullinated peptide testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. <i>Arthritis and Rheumatism</i> , 2009, 60, 2211-2215.	6.7	26

#	ARTICLE	IF	CITATIONS
145	Impact of interactions of cigarette smoking with <i>NAT2</i> polymorphisms on rheumatoid arthritis risk in African Americans. <i>Arthritis and Rheumatism</i> , 2012, 64, 655-664.	6.7	26
146	Complementary and Alternative Medicine Use in African Americans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 180-189.	3.4	26
147	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 576-581.	3.4	25
148	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , 2013, 45, 468-469.	21.4	24
149	Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug. <i>Arthritis Care and Research</i> , 2019, 71, 521-529.	3.4	24
150	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e50.	4.3	24
151	Immunohistologic demonstration of type ii collagen in synovial fluid phagocytes of osteoarthritis and rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 1989, 32, 1458-1464.	6.7	23
152	Transforming growth factor β^2 within fibrotic scleroderma lungs. <i>American Journal of Medicine</i> , 1992, 93, 628-636.	1.5	23
153	Genetic variants of STAT4 associated with rheumatoid arthritis in persons of Asian and European ancestry do not replicate in African Americans. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 625-626.	0.9	22
154	14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in T C 2 and CD8 + lymphocytes from patients with scleroderma. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 109-119.e6.	2.9	22
155	Contraception Use Among Reproductive-Age Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2019, 71, 1132-1140.	3.4	22
156	Colchicine and gout. <i>Arthritis and Rheumatism</i> , 1991, 34, 782-786.	6.7	21
157	Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. <i>Arthritis and Rheumatism</i> , 2004, 51, 933-940.	6.7	21
158	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	2.1	21
159	Growth factors, extracellular matrix, and oncogenes in scleroderma. <i>Arthritis and Rheumatism</i> , 1992, 35, 304-310.	6.7	20
160	Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R75.	3.5	20
161	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	2.0	20
162	Effects of Nonsteroidal Antiinflammatory Drugs on Bone Loss in Chronic Inflammatory Disease. <i>Annals of the New York Academy of Sciences</i> , 1993, 696, 292-302.	3.8	19

#	ARTICLE	IF	CITATIONS
163	Certolizumab pegol: a new biologic targeting rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 855-866.	3.0	19
164	Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial. <i>Journal of Rheumatology</i> , 2013, 40, 572-578.	2.0	19
165	Improvement in Herpes Zoster Vaccination in Patients with Rheumatoid Arthritis: A Quality Improvement Project. <i>Journal of Rheumatology</i> , 2017, 44, 11-17.	2.0	19
166	Practice Pattern Variation Among Internal Medicine Specialists in the Prevention of Glucocorticoid-Induced Osteoporosis. <i>Journal of Clinical Rheumatology</i> , 2000, 6, 117-122.	0.9	17
167	POTENTIAL BIOLOGIC AGENTS FOR TREATING RHEUMATOID ARTHRITIS. <i>Rheumatic Disease Clinics of North America</i> , 2001, 27, 445-491.	1.9	17
168	New Therapeutic Approaches to the Management of Rheumatoid Arthritis. <i>BioDrugs</i> , 2001, 15, 379-393.	4.6	17
169	Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1804-1810.	3.4	17
170	Analysis of CXCR5+Th17 cells in relation to disease activity and TNF inhibitor therapy in Rheumatoid Arthritis. <i>Scientific Reports</i> , 2016, 6, 39474.	3.3	17
171	Cardiovascular Disease Risk in Patients with Rheumatic Diseases. <i>Clinics in Geriatric Medicine</i> , 2017, 33, 105-117.	2.6	17
172	Febuxostat " Treatment for Hyperuricemia and Gout?. <i>New England Journal of Medicine</i> , 2005, 353, 2505-2507.	27.0	16
173	Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. <i>PLoS ONE</i> , 2021, 16, e0244187.	2.5	16
174	Biologic Therapies on the Horizon for Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2004, 10, S32-S39.	0.9	15
175	Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. <i>Clinical Immunology</i> , 2007, 123, 235-243.	3.2	13
176	Socioeconomic Disparities in the Health of African Americans With Rheumatoid Arthritis From the Southeastern United States. <i>Arthritis Care and Research</i> , 2014, 66, 1808-1817.	3.4	13
177	Induction Therapy with Combination TNF Inhibitor and Methotrexate in Early Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 417.	4.7	13
178	Socioeconomic factors and self-reported health outcomes in African Americans with rheumatoid arthritis from the Southeastern United States: the contribution of childhood socioeconomic status. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 10.	1.9	13
179	New Approaches to the Therapy of Autoimmune Diseases: Rheumatoid Arthritis As a Paradigm. <i>American Journal of the Medical Sciences</i> , 1993, 305, 40-51.	1.1	12
180	THE USE OF ANALGESICS IN THE MANAGEMENT OF PAIN IN RHEUMATIC DISEASES. <i>Rheumatic Disease Clinics of North America</i> , 1999, 25, 153-191.	1.9	12

#	ARTICLE	IF	CITATIONS
181	B cells in rheumatoid arthritis synovial tissues encode focused antibody repertoires that include antibodies that stimulate macrophage TNF- α production. <i>Clinical Immunology</i> , 2020, 212, 108360.	3.2	12
182	T-CELL RECEPTOR PEPTIDE VACCINATION IN THE TREATMENT OF RHEUMATOID ARTHRITIS. <i>Rheumatic Disease Clinics of North America</i> , 1998, 24, 641-650.	1.9	11
183	Clinical and pharmacological experience with etanercept. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 1443-1451.	4.1	11
184	An African Ancestry-Specific Allele of CTLA4 Confers Protection against Rheumatoid Arthritis in African Americans. <i>PLoS Genetics</i> , 2009, 5, e1000424.	3.5	11
185	Rheumatoid Arthritis in the Women's Health Initiative: Methods and Baseline Evaluation. <i>American Journal of Epidemiology</i> , 2014, 179, 917-926.	3.4	11
186	Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis. <i>Arthritis Care and Research</i> , 2020, 73, 1372-1378.	3.4	11
187	The Use of Methotrexate Perioperatively in Patients with Rheumatoid Arthritis Undergoing Major Joint Replacement Surgery. <i>Journal of Clinical Rheumatology</i> , 1996, 2, 6-8.	0.9	10
188	Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 11-18.	1.9	9
189	Analysis of Complement Gene Expression, Clinical Associations, and Biodistribution of Complement Proteins in the Synovium of Early Rheumatoid Arthritis Patients Reveals Unique Pathophysiologic Features. <i>Journal of Immunology</i> , 2022, 208, 2482-2496.	0.8	9
190	Synovial Biopsy of the Knee Joint under Direct Visualization by Needle Arthroscopy. <i>Journal of Clinical Rheumatology</i> , 1995, 1, 103-109.	0.9	8
191	Cytokines as Targets for Anti-inflammatory Agents. <i>Annals of the New York Academy of Sciences</i> , 2009, 1182, 88-96.	3.8	8
192	Pain and Catastrophizing in Patients With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 232-236.	0.9	8
193	Improving Pneumococcal Vaccination Rates in Rheumatology Patients by Using Best Practice Alerts in the Electronic Health Records. <i>Journal of Rheumatology</i> , 2021, 48, 1472-1479.	2.0	8
194	Rheumatoid arthritis patients and clinical drug trials A case-control study. <i>Arthritis and Rheumatism</i> , 1991, 4, 22-26.	6.7	7
195	Health status response of rheumatoid arthritis to treatment with DAB486IL-2. <i>Arthritis and Rheumatism</i> , 1996, 9, 112-119.	6.7	7
196	Rheumatoid arthritis: developing pharmacological therapies. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 927-935.	4.1	7
197	Predictive Value of Autoantibody Testing for Validating Self-reported Diagnoses of Rheumatoid Arthritis in the Women's Health Initiative. <i>American Journal of Epidemiology</i> , 2013, 177, 887-893.	3.4	7
198	Associations of Alcohol Use with Radiographic Disease Progression in African Americans with Recent-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1498-1504.	2.0	7

#	ARTICLE	IF	CITATIONS
199	Recent Advances in Anti-Tumour Necrosis Factor (TNF) Therapy in Rheumatoid Arthritis. <i>BioDrugs</i> , 1999, 11, 201-210.	4.6	6
200	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018, 13, e0205768.	2.5	6
201	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	2.0	6
202	Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 785-786.	0.9	5
203	Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women's Health Initiative Rheumatoid Arthritis Study. <i>American Journal of Epidemiology</i> , 2017, 186, 245-254.	3.4	5
204	Adalimumab in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004, 6, 333-4.	4.7	5
205	Adalimumab in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004, 6, 333-334.	4.7	4
206	Inflammatory joint diseases and atherosclerosis: time to look beyond the "lipid paradox". <i>Current Opinion in Lipidology</i> , 2019, 30, 342-349.	2.7	4
207	Post-GWAS functional studies reveal an RA-associated CD40-induced NF- κ B signal transduction and transcriptional regulation network targeted by class II HDAC inhibitors. <i>Human Molecular Genetics</i> , 2021, 30, 823-835.	2.9	4
208	Transcriptional Regulation of CD40 Expression by 4 Ribosomal Proteins via a Functional SNP on a Disease-Associated CD40 Locus. <i>Genes</i> , 2020, 11, 1526.	2.4	4
209	A review of biosimilars for rheumatoid arthritis. <i>Current Opinion in Pharmacology</i> , 2022, 64, 102234.	3.5	4
210	How do we best measure the clinical benefit of a structure-modifying osteoarthritis drug?. <i>Osteoarthritis and Cartilage</i> , 2004, 12, 61-62.	1.3	3
211	Infliximab in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004, 6, 334-335.	4.7	3
212	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3 ^A —3 Methodology Applied to Two Active Comparator Trials. <i>Arthritis Care and Research</i> , 2019, 71, 319-322.	3.4	3
213	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 98-101.	0.8	3
214	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 114-118.	0.8	3
215	Vaccination Against Rheumatoid Arthritis. <i>BioDrugs</i> , 1997, 8, 87-95.	4.6	2
216	The treatment of rheumatoid arthritis: A review of recent clinical trials. <i>Current Rheumatology Reports</i> , 1999, 1, 135-138.	4.7	2

#	ARTICLE	IF	CITATIONS
217	Predicting outcomes in early rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2002, 4, 193-194.	4.7	2
218	JAK Inhibition in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2011, 13, 379-380.	4.7	2
219	Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 488-497.	2.5	2
220	Hypothyroidism in vasculitis. <i>Rheumatology</i> , 2022, 61, 2942-2950.	1.9	2
221	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	1.4	2
222	Comment on the article by Furst et al. <i>Arthritis and Rheumatism</i> , 1989, 32, 1631-1632.	6.7	1
223	Improved methotrexate patient information. <i>Arthritis and Rheumatism</i> , 1995, 38, 874-875.	6.7	1
224	Genetic Influences on Rheumatoid Arthritis in African Americans. <i>Immunologic Research</i> , 2002, 26, 015-026.	2.9	1
225	B cell targeted therapy: a new approach to the treatment of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2005, 7, S1.	3.5	1
226	Certolizumab pegol in active rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009, 11, 311-312.	4.7	1
227	Tocilizumab versus methotrexate in moderate to severe rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009, 11, 313-314.	4.7	1
228	Reply. <i>Arthritis and Rheumatology</i> , 2016, 68, 555-556.	5.6	1
229	Etanercept and methotrexate combination in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004, 6, 333.	4.7	1
230	Viral arthritis in humans. <i>Current Opinion in Rheumatology</i> , 1989, 1, 185-193.	4.3	0
231	Achieving consensus on an algorithm for the treatment of rheumatoid arthritis with methotrexate. <i>Arthritis and Rheumatism</i> , 1990, 3, 53-57.	6.7	0
232	ASSESSMENT OF NEEDLE ARTHROSCOPY. <i>Journal of Clinical Rheumatology</i> , 1995, 1, 255.	0.9	0
233	Title is missing!. <i>Arthritis Research</i> , 2000, 1, S47.	2.0	0
234	Humanized anti-interleukin-6 receptor antibody. <i>Current Rheumatology Reports</i> , 2005, 7, 381-381.	4.7	0

#	ARTICLE	IF	CITATIONS
235	Efficacy of costimulation blockade with abatacept in rheumatoid arthritis patients refractory to tumor necrosis factor- α inhibition. <i>Current Rheumatology Reports</i> , 2006, 8, 367-367.	4.7	0
236	Efficacy and safety of rituximab in rheumatoid arthritis patients refractory to methotrexate. <i>Current Rheumatology Reports</i> , 2006, 8, 368-368.	4.7	0
237	Methotrexate versus combination methotrexate and etanercept for rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009, 11, 309-310.	4.7	0
238	Inhibition of Spleen Tyrosine Kinase for Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2011, 13, 377-378.	4.7	0
239	Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2011, 13, 381-382.	4.7	0
240	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 539-540.	6.7	0
241	Identifying Vulnerable Plaque in Rheumatoid Arthritis Using Novel Microbubble Contrast-Enhanced Carotid Ultrasonography and Serum Biomarkers. <i>Journal of Diagnostic Medical Sonography</i> , 2020, 36, 300-310.	0.3	0